• Bloomberg
• BusinessWeek
• Business Exchange

Intercell

Vienna, Austria
Biotechnology
CEO: Gerd Zettlemeissl, 53

Intercell is developing vaccines that target viruses and bacteria causing a wide range of ailments, from influenza and tuberculosis to Japanese encephalitis. The company analyzes the molecular structures of disease-causing pathogens, then chemically synthesizes them into "smart" vaccines that can help the immune system recognize and kill the pathogens. It also adds "immunizers" that stimulate T-Cells, a type of blood cell that protects the body from infection.

next slide previous slide